Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Bayer Intellectual Property Gmbh

Adverio Pharma Gmbh

Bayer Schering Pharma Ag

Peter Sandner

Peter Kolkhof

Johannes-Peter Stasch

Andreas Knorr

Markus Follmann

Michael Hahn

Georges Von Degenfeld

Frank Wunder

Alexandros Vakalopoulos

Carsten Schmeck

Hans-Georg Lerchen

Hanna Tinel

Ilka Mathar

Bernd Riedl

Daniel Meibom

Claudia Hirth-Dietrich

Barbara Albrecht-Küpper

Lisa Dietz

Jürgen Klar

Timo Stellfeld

Thomas Mondritzki

Alexey Gromov

Martina Klein

Joachim Hütter

Friedrich Grimminger

Olaf Christensen

Lucas Hudson Hofmeister

Andre Philippe Dieskau

Robert Alan Webster

Nuria Ortega Hernandez

Marie-Pierre Collin-kröpelin

Reiner Frey

Melissa Boultadakis-arapinis

Lisa Candish

Stephen Dawe

Janethe De Oliveira Pena

Melanie Hemmrich

Stefanie Breitenstein

Jan Dreher

Michael-Friedrich Boettcher

Andre Dieskau

Hahn Michael G

Michael G Hahn

Ralph Schermuly

Michael-Friedrich Böttcher

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

Substituted pyrazolo piperidine carboxylic acids

The present invention relates to the combination of stimulators of soluble guanylate cyclase (sGC stimulators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.

Combination containing sGC stimulators and mineralocorticoid receptor antagonists

The present invention relates to a method of identifying a subgroup of patients suffering from diffuse cutaneous systemic sclerosis (dcSSc) which subgroup of patients benefits from a treatment with at least one sGC stimulator and/or sGC activator in a higher degree than patients not belonging to this subgroup.

Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group

The present invention relates to non-steriodal mineralocorticoid receptor (MR) and the pharmacology of mineralocorticoid receptor antagonists (MR Antagonists, MRAs). In particular, the invention relates to the use of MRAs alone and in combination preferably in combination with sGC stimulators and/or sGC activators for preparation of medicaments for the prevention and/or treatment of muscular or neuromuscular diseases, especially for the treatment of Duchenne Muscular Dystrophy (DMD).

Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases

The present invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.

Combination containing sGC activators and mineralocorticoid receptor antagonists

Combination containing SGC stimulators and mineralocorticoid receptor antagonists

The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors (PDE5i) in combination with a) treatments, leading to increased cGMP mobilization, and/or b) tretaments correcting and/or potentiatiating CFTR function, and/or c) treatments currently used as standard of care in Cystic Fibrosis, and/or d) antinflammatory treatments for the preparation of medicaments for the treatment of Cystic Fibrosis (CF) with improved efficacy over methods of treatments already known.

SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis

The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.

Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)

The present invention relates to the use of selective adenosine A1 agonists, in particular the dicyanopyridines of formula (I), for the treatment and/or prophylaxis of glaucoma and ocular hypertension as well as the their use for the production of a medicament for the treatment and/or prophylaxis of glaucoma and ocular hypertension.

Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension

The present invention relates to pharmaceutical compositions and combinations for treating, preventing or managing pulmonary hypertension comprising small molecule heterocyclic pharmaceuticals, and more particularly, substituted pyridines and pyridazines optionally combined with at least one additional therapeutic agent.

Compounds for treating pulmonary hypertension

Growing community of inventors

Wuppertal, Germany

Peter Sandner